Establishing a nanoluciferase-based assay as a high-throughput screening platform for therapeutics in congenital nephrotic syndrome
Journal of Pharmacological Sciences · 2025
DOI: 10.1016/j.jphs.2025.09.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacological Sciences, 2025. Verfasst von Haruki Tsuhako und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Membrane Proteins, Nephrotic Syndrome, High-Throughput Screening Assays, Luciferases. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science, Ministry of Education, Culture, Sports, Science and Technology, Kumamoto University.
Abstract (Originalsprache)
Nephrin is crucial for the formation of the glomerular slit diaphragm, which is the final filtration barrier in the kidney. A mutation in the NPHS1 gene that codes for nephrin causes congenital nephrotic syndrome of the Finnish type (CNF). Most missense mutations render nephrin non-functional due to the defective nephrin trafficking to the cell membrane. Pharmacological approaches that induce the expression of nephrin on the cell membrane are feasible, but therapeutic development is hampered by the lack of a high-throughput screening (HTS) system. Here, we developed a nanoluciferase HiBiT-based HTS platform to quantify the cell membrane expression of a nephrin mutant. This evaluation system reflected the previously reported results of various nephrin mutant localization. Using this system, we screened and identified 10 compounds that promoted the expression of the nephrin E725D mutant on the cell membrane. Moreover, the phosphorylation and N-glycosylation of nephrin, which are modifications that indicate its cell surface localization, correlated with the luminescence values of HiBiT-Nephrin in the compound screening. Consequently, this HiBiT-Nephrin evaluation system could be a new platform for predicting the pathogenicity of variants and searching for therapeutic agents for CNF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Molecular Medicine, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan; Global Center for Natural Resources Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto,…
- Department of Kidney Development, Institute of Molecular Embryology and Genetics, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan.
Förderung
- Japan Society for the Promotion of Science
- Ministry of Education, Culture, Sports, Science and Technology
- Kumamoto University
- Japan Agency for Medical Research and Development
Zitieren
APA
Tsuhako, H., Suico, M. A., Kojima, H., Takahashi, S., Tanigawa, S., Kamura, M., Sato, R., Kato, R., Owaki, A., Nishinakamura, R., Shuto, T., & Kai, H. (2025). Establishing a nanoluciferase-based assay as a high-throughput screening platform for therapeutics in congenital nephrotic syndrome. Journal of Pharmacological Sciences. https://doi.org/10.1016/j.jphs.2025.09.006
Vancouver
Tsuhako H, Suico MA, Kojima H, Takahashi S, Tanigawa S, Kamura M, et al. Establishing a nanoluciferase-based assay as a high-throughput screening platform for therapeutics in congenital nephrotic syndrome. Journal of Pharmacological Sciences. 2025. doi:10.1016/j.jphs.2025.09.006
BibTeX
@article{Tsuhako2025,
author = {Tsuhako, Haruki and Suico, Mary Ann and Kojima, Haruka and Takahashi, Saki and Tanigawa, Shunsuke and Kamura, Misato and Sato, Ryoichi and Kato, Riko and Owaki, Aimi and Nishinakamura, Ryuichi and Shuto, Tsuyoshi and Kai, Hirofumi},
title = {Establishing a nanoluciferase-based assay as a high-throughput screening platform for therapeutics in congenital nephrotic syndrome},
journal = {Journal of Pharmacological Sciences},
year = {2025},
doi = {10.1016/j.jphs.2025.09.006}
}
EUVIMED